Jane Street’s Mineralys Therapeutics MLYS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$5.41M Buy
+215,209
New +$5.86M ﹤0.01% 3620
2025
Q4
– Sell
-37,145
Closed -$1.49M – 11905
2025
Q3
$1.41M Buy
+37,145
New +$803K ﹤0.01% 5597
2024
Q4
– Sell
-15,855
Closed -$192K – 10119
2024
Q3
$192K Sell
15,855
-6,940
-30% -$84K ﹤0.01% 8673
2024
Q2
$267K Buy
22,795
+8,609
+61% +$108K ﹤0.01% 7973
2024
Q1
$183K Buy
+14,186
New +$175K ﹤0.01% 8236
2023
Q4
– Sell
-43,057
Closed -$409K – 9570
2023
Q3
$409K Buy
+43,057
New +$561K ﹤0.01% 6586

Other funds holding MLYS

Jane Street's MLYS Position: Q3 2026 in Review

Jane Street opened a new position in Mineralys Therapeutics (MLYS) in Q3 2026: 215,209 shares worth $5.41M. The stake represents ﹤0.01% of the portfolio and ranks #3620 among its holdings. This is a return to the name: Jane Street previously reported a position in MLYS as recently as Q3 2025.

Jane Street first reported a position in MLYS in Q3 2023 and has held it in 6 quarters since. 219 funds tracked by Wall St. Rank hold MLYS as of Q3 2026.

  • Jane Street held 215,209 shares of Mineralys Therapeutics worth $5.41M as of Q3 2026.
  • Mineralys Therapeutics was a new Jane Street position in Q3 2026.
  • Mineralys Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q3 2026, its #3620 holding.
  • Jane Street first reported a position in Mineralys Therapeutics in Q3 2023 and has held it in 6 quarters since.
  • 219 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q3 2026.

Based on Jane Street's 13F filing for Q3 2026, filed 12 Nov 2026.